

Exercise of options and PDMR dealing

Levember 31, 2/24 7:00 AM EST
var w=window,if(w.performance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerformance)|w.msPerforman



MaxCyte, Inc. ("MaxCyte" or the "Company")

Exercise of options and PDMR dealing

ROCKVILLE, MD, December 31, 2024: MaxCyte Inc., (NASDAC: MXCT; LS: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 26 December 2024, as per a filling lodged with the U.S. Securities and Exchange Commission, John Johnston, a Non-Executive Director of the Company, exercised optons over 3,000 shares of common stock of 50.01 of the Company ("Common Stock") ("Exercise") in aggregate. The John other wishers of Common Stock were issued pursuant to the Company's existing its block admission facility and were sold by John Johnston at a price range between 5,399 sand 4,060 per Common Stock ("Sale"). The sold shares represent approximately 0,9% of John Johnston's total equity and option holdings in the Company's stock capital, respectively.

Following the Exercise and Sale, John Johnston holds 120,583 shares of Common Stock representing 0.1% of the Issued stock capital of the Company, Following the Exercise, John Johnston holds a Further 174,918 options over Common Stock and 21,357 restricted stock units.

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by John Johnston on 19 December 2023 relating solely to the sale of shares acquired from exercise of options that expire on 18 July 2028.

MaxCyte Contacts:

US IR Adviser Gilmartin Group David Deuchler, CFA

+1 415-937-5400 ir@maxcyte.com

+44 (0)20 7886 2500

Nominated Adviser and Joint Corporate Broker Panmure Liberum Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden

UK IR Adviser ICR Healthcare Mary-Jane Elliott Chris Welsh

+44 (0)203 709 5700

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 25 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection worldlow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT* platform, which is based on our flow fleetroporation* technology, has been designed to support the applied pepanding cell therapy market and can be utilized across the continuous or the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The cell-based medicines in the cell-based medicines where the cell-based processing assembles or discoasies; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at <u>maxcde.com</u> and follow us on <u>X</u> and <u>Linkedin</u>.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated			
a)	Name	John Johnston		
2	Reason for the notification			
a)	Position/status	Non-Executive Director		
b)	Initial notification /Amendment	Initial notification		
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	MaxCyte, Inc.		
b)	LEI	54930053YHXULRFCU991		
4		section to be repeated for (i) each type of instrument; (ii) each date; and (iv) each place where transactions have been		
a)	Description of the financial instrument, type of instrument	Common Stock of \$0.01 each		
	Identification code	US57777K1060		
b)	Nature of the transaction	Exercise of Options over common stock		
c)	Price(s) and volume(s)	Exercise Price(s) Volume(s)		
d)	Aggregated information			
	- Aggregated volume	3,000		
	- Price	\$2.932		
e)	Date of the transaction	26 December 2024		
f)	Place of the transaction	US Stock Exchange, Nasdaq		

1	L	Details of the person discharging managerial responsibilities / person closely associated		
а	1 (1	Name	John Johnston	
2	. F	Reason for the notification		
а	i) F	Position/status	Non-Executive Director	

b)	Initial notification /Amendment	Initial notification				
3	Details of the issuer, emission all or auction monitor	etails of the issuer, emission allowance market participant, auction platform, auctioneer auction monitor				
a)	Name	MaxCyte, Inc.				
b)	LEI	54930053YHXULRFCU991				
4		ion to be repeated for (i) each type of instrument; (ii) h date; and (iv) each place where transactions have been				
a)	Description of the financial instrument, type of instrument	Common Stock of \$0.01 each				
	Identification code	USS7777K1060				
b)	Nature of the transaction	Sale of common stock				
c)	Price(s) and volume(s) Aggregated information	Exercise Price(s) \$3.9950 \$4.0000 \$4.0000 \$54.0010 \$4.0010 \$54.0110 \$54.0110 \$54.0150 \$54.0000 \$54.0000 \$54.0000	Volume(s) 210 210 2431 2431 200 50 300 200 200 200 200 56 57 58 58 58 59 59 59 59 59 59 59 59 59 59 59 59 59			
	- Aggregated volume	3,000 \$4.0065				
e)	Date of the transaction	26 December 2024				
f)	Place of the transaction	US Stock Exchange, Nasdaq				

This information is provided by RNS, the news service of the London Stock Exchange, RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply, For further information, please contact ms/lifesq.com or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, pleases see our <u>Privacy Public</u> see our <u>Privacy Public</u>.

END

DSHEAXAEDFSLFFA